PDX1 and familial pancreatic carcinoma: Combined with the overexpression of PDX-1 found in human specimens of pancreatic neuroendocrine tumors and nesidioblastosis, these data demonstrate that PDX-1 is a potential therapeutic target for pancreatic cancer, insulinonoma and islet neoplasia using a novel RNAi effector platform.